Major life sciences roundtable debate reveals growth in regulatory outsourcing
Growth due to increasing complexity around affiliates’ roles.
A major industry debate by a Who’s Who of the life sciences industry has revealed growing interest in outsourcing of regulatory affairs (RA) activities due to the increased complexity in the role of international affiliate organisations. The debate’s findings, which have been distilled into a summary paper published by outsourcing and consulting services specialist ProductLife Group (PLG), will be aired via an exclusive webinar on 12 April.
The PLG Evolve roundtable debate, Brave New World: Outsourcing and the Changing Role of the Affiliate, brings together senior representatives from Merck, LEO Pharma, AbbVie, Sanofi and Lundbeck. During this seminal session, they debate the conflicting needs of local sales operations and corporate RA teams, and the role of specialist external services in helping to bridge these differences.
The panelists discuss variants in affiliate operating models, and explore how an outsourced approach to managing local regulatory activities, as well as safety documentation and managing safety case reports, can help overcome current challenges, enabling in-country affiliates to focus on building the business unfettered by administrative bureaucracy, while ensuring the quality, consistency and transparency needed at a corporate level to achieve compliance.
In the words of panellist Jesper Kihl, Vice President for Global Regulatory Affairs at LEO Pharma: “The environment in which we operate has become far more complex, margins are being squeezed, and room for manoeuvre is shrinking. Affiliates need to focus on commercial activities, so outsourcing regulatory, pharmacovigilance, and other activities, makes sense.”
The PLG Evolve virtual discussion covers concerns about and first-hand experiences of outsourcing affiliate RA and pharmacovigilance documentation activities, including the learning curve involved when shifting from internally managed processes to the outsourcing of affiliate administrative activities.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance